Réza Elaidi

2.9k total citations
34 papers, 881 citations indexed

About

Réza Elaidi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Réza Elaidi has authored 34 papers receiving a total of 881 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Réza Elaidi's work include Renal cell carcinoma treatment (18 papers), Renal and related cancers (10 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Réza Elaidi is often cited by papers focused on Renal cell carcinoma treatment (18 papers), Renal and related cancers (10 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Réza Elaidi collaborates with scholars based in France, Belgium and United States. Réza Elaidi's co-authors include Stéphane Oudard, Benoit Beuselinck, Yann Vano, Jessica Zucman‐Rossi, Jacques Médioni, Alexandra Karadimou, Constance Thibault, Florian Scotté, Arnaud Méjean and Patrick Schöffski and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Réza Elaidi

32 papers receiving 871 citations

Peers

Countries citing papers authored by Réza Elaidi

Since Specialization

Citations

This map shows the geographic impact of Réza Elaidi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Réza Elaidi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Réza Elaidi more than expected).

Fields of papers citing papers by Réza Elaidi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Réza Elaidi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Réza Elaidi. The network helps show where Réza Elaidi may publish in the future.

Co-authorship network of co-authors of Réza Elaidi

This figure shows the co-authorship network connecting the top 25 collaborators of Réza Elaidi. A scholar is included among the top collaborators of Réza Elaidi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Réza Elaidi. Réza Elaidi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer 2024 ·SHILAP Revista de lepidopterología ·(unknown), Réza Elaidi, (unknown), Hélène Blons, (unknown), Laure Gibault, Elizabeth Fabre	1
2	A conceptual framework for cautious escalation of anticancer treatment: How to optimize overall benefit and obviate the need for de-escalation trials 2024 ·Cancer Treatment Reviews ·(unknown), (unknown), Réza Elaidi, Dario Trapani, Florian Strasser, Gerard Vreugdenhil, Mike Clarke	0
3	Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression 2023 ·Cancers ·(unknown), Réza Elaidi, (unknown), (unknown), (unknown), Mohammed Ismaili, Laure Fournier, Bastien Rance, Laure Gibault, (unknown), (unknown), Elizabeth Fabre	3
4	Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel 2022 ·Cancers ·(unknown), Réza Elaidi, Olivier Colomban, Denis Maillet, Michel Tod, Benoît You, Stéphane Oudard	4
5	BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer 2020 ·Bulletin du Cancer ·Nicolas Epaillard, Audrey Simonaggio, Réza Elaidi, (unknown), (unknown), Constance Thibault, Cheng‐Ming Sun, Marco Moreira, Stéphane Oudard, Yann Vano	35
6	Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO 2020 ·Bulletin du Cancer ·Constance Thibault, Réza Elaidi, Yann Vano, (unknown), (unknown), (unknown), François Audenet, Stéphane Oudard	12
7	Impact des signatures moléculaires sur le choix du traitement systémique du cancer du rein métastatique 2020 ·Bulletin du Cancer ·Audrey Simonaggio, Nicolas Epaillard, Réza Elaidi, Cheng‐Ming Sun, Marco Moreira, Stéphane Oudard, Yann Vano	4
8	Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis 2020 ·Cancers ·Réza Elaidi, (unknown), Delphine Borchiellini, Philippe Barthélémy, Alain Ravaud, Stéphane Oudard, Yann Vano	18
9	Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients 2018 ·PLoS ONE ·Yann Vano, Stéphane Oudard, (unknown), (unknown), Constance Thibault, (unknown), Florian Scotté, Réza Elaidi	62
10	Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges 2017 ·PubMed ·Laure Fournier, Alexandre Bellucci, Yann Vano, (unknown), Constance Thibault, Réza Elaidi, Stéphane Oudard, C.A. Cuénod	5
11	Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma 2017 ·BMC Cancer ·(unknown), Réza Elaidi, (unknown), (unknown), (unknown), Brigitte Sabatier, Stéphane Oudard, Jacques Médioni	7
12	Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study 2017 ·Contemporary Clinical Trials Communications ·Jacques Médioni, (unknown), Réza Elaidi, Paul F. Reid, (unknown), Dorothy Bray	16
13	Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma 2017 ·Clinical Genitourinary Cancer ·Édouard Auclin, (unknown), (unknown), (unknown), (unknown), Laure Fournier, (unknown), (unknown), Yann Vano, Constance Thibault, Florence Joly, L. Brunereau, Carlos Gomez‐Roca, Christine Chevreau, Réza Elaidi, Stéphane Oudard	25
14	Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study 2016 ·Clinical Genitourinary Cancer ·(unknown), Réza Elaidi, Mustafa Özgüroğlu, (unknown), Hélène Gauthier, Stéphane Culine, Armelle Caty, (unknown), Édouard Auclin, (unknown), Pierre Combe, Éric Tartour, Stéphane Oudard	8
15	Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases 2016 ·Annals of Oncology ·Réza Elaidi, Yann Vano, Nicolas Aide, Laure Fournier, Désirèe Deandreis, Florence Tenenbaum, Rachida Lebtahi, (unknown), Laurence Albigès, Bernard Escudier, Florence Joly, J. Alexandre, Michela Bernardini, Stéphanie Baron, Julia Arfi‐Rouche, Cory V. Noel, (unknown), John O’Quigley, Jacques Médioni, Stéphane Oudard	36
16	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting 2015 ·Clinical Cancer Research ·Benoit Beuselinck, Sylvie Job, Étienne Becht, Alexandra Karadimou, Virginie Verkarre, Gabrielle Couchy, Nicolás A. Giraldo, Nathalie Rioux‐Leclercq, Vincent Molinié, Mathilde Sibony, Réza Elaidi, (unknown), Jean‐Jacques Patard, Arnaud Méjean, Wolf H. Fridman, Catherine Sautès‐Fridman, Aurélien de Reyniès, Stéphane Oudard, Jessica Zucman‐Rossi	230
17	Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases 2012 ·British Journal of Cancer ·Benoit Beuselinck, Pascal Wolter, Alexandra Karadimou, Réza Elaidi, Herlinde Dumez, Anne Rogiers, Thomas Van Cann, Ludo Willems, J.J. Body, J. Berkers, Hendrik Van Poppel, Evelyne Lerut, Philip R. Debruyne, Robert Paridaens, Patrick Schöffski	86
18	A practical approach to improve safety and management in chemotherapy units based on the PROCHE – Programme for optimisation of the chemotherapy network monitoring program 2012 ·European Journal of Cancer ·Florian Scotté, Stéphane Oudard, (unknown), Réza Elaidi, Brigitte Bonan	30
19	Carcinome rénal : état des lieux de la prise en charge des métastases cérébrales 2012 ·Bulletin du Cancer ·(unknown), P. Giraud, Philippe Meneï, Jacques Médioni, Réza Elaidi, Pierre Combe, Stéphane Oudard	2
20	Inhibiteurs de l’angiogenèse : revues de l’apport thérapeutique du sorafenib, du sunitinib et du bevacizumab dans le cancer du rein métastatique 2010 ·Bulletin du Cancer ·Eduardo Barrascout, Jacques Médioni, Florian Scotté, J. Ayllón, Arnaud Méjean, C.A. Cuénod, Éric Tartour, Réza Elaidi, Stéphane Oudard	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact